Lornoxicam

$79$264

Products Details

Product Description

– Lornoxicam (Chlortenoxicam) is a highly active COX-1 and COX-2 inhibitor with IC50 of 5 nM and 8 nM respectively. It is a new non-steroidal anti-inflammatory compound.

Web ID

– HY-B0367

Storage Temperature

– -20°C, 3 years; 4°C, 2 years (Powder)

Shipping

– Room Temperature

Applications

– COVID-19-immunoregulation

Molecular Formula

– C13H10ClN3O4S2

References

– [1]Spyra S, et al. COX-2-selective inhibitors celecoxib and deracoxib modulate transient receptor potential vanilloid 3 channels. Br J Pharmacol. 2017 Aug;174(16):2696-2705.|[2]Rose, P. and C. Steinhauser, Comparison of Lornoxicam and Rofecoxib in Patients with Activated Osteoarthritis (COLOR Study). Clin Drug Investig, 2004. 24(4): p. 227-36.|[3]Bianchi, M. and A.E. Panerai, Effects of lornoxicam, piroxicam, and meloxicam in a model of thermal hindpaw hyperalgesia induced by formalin injection in rat tail. Pharmacol Res, 2002. 45(2): p. 101-5.

CAS Number

– 70374-39-9

Molecular Weight

– 371.82

Compound Purity

– 99.84

SMILES

– O=C(C1=C(O)C2=C(C=C(Cl)S2)S(N1C)(=O)=O)NC3=NC=CC=C3

Clinical Information

– Launched

Research Area

– Inflammation/Immunology

Solubility

– DMSO : 3.8 mg/mL (ultrasonic;warming)

Target

– COX;Endogenous Metabolite

Isoform

– COX-1;COX-2

Pathway

– Immunology/Inflammation;Metabolic Enzyme/Protease

Product type

– Natural Products

Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

=

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.

=